A phase 1b study investigated the clinical efficacy and safety of duligotuzumab, a dual action humanized IgG1 mAb that targets EGFR and HER3, in combination with chemotherapy in the treatment of patients with recurrent or metastatic HNSCC. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.